After putting up evidence to show that the liver toxicity triggered by its lead drug can be reversed, the FDA has lifted the full hold placed on its lead–and only–cancer drug. And investors responded enthusiastically to the biotech’s return to the clinic, boosting shares by 35% in premarket trading.

…read more

Source: Geron shares rocket up after FDA takes the cuffs off its lead drug


0 No comments